• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Advanced Functional Materials >Precise Molecular Engineering of Photosensitizers with Aggregation-Induced Emission over 800 nm for Photodynamic Therapy
【24h】

Precise Molecular Engineering of Photosensitizers with Aggregation-Induced Emission over 800 nm for Photodynamic Therapy

机译：聚合诱导的800纳米以上光发射的光敏剂的精确分子工程，用于光动力治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Owing to efficient singlet oxygen (O-1(2)) generation in aggregate state, photosensitizers (PSs) with aggregation-induced emission (AIE) have attracted much research interests in photodynamic therapy (PDT). In addition to high O-1(2) generation efficiency, strong molar absorption in long-wavelength range and near-infrared (NIR) emission are also highly desirable, but difficult to achieve for AIE PSs since the twisted structures in AIE moieties usually lead to absorption and emission in short-wavelength range. In this contribution, through acceptor engineering, a new AIE PS of TBT is designed to show aggregation-induced NIR emission centered at 810 nm, broad absorption in the range between 300 and 700 nm with a large molar absorption coefficient and a high O-1(2) generation efficiency under white light irradiation. Further, donor engineering by attaching two branched flexible chains to TBT yielded TBTC8, which circumvented the strong intermolecular interactions of TBT in nanoparticles (NPs), yielding TBTC8 NPs with optimized overall performance in O-1(2) generation, absorption, and emission. Subsequent PDT results in both in vitro and in vivo studies indicate that TBTC8 NPs are promising candidates in practical application.
机译：由于以聚集态有效产生单线态氧（O-1（2）），具有聚集诱导发射（AIE）的光敏剂（PSs）在光动力疗法（PDT）中引起了许多研究兴趣。除了具有高的O-1（2）生成效率外，还非常需要长波长范围内的强摩尔吸收和近红外（NIR）发射，但是对于AIE PS，由于AIE部分中的扭曲结构通常导致扭曲，因此很难实现在短波长范围内的吸收和发射。在这一贡献中，通过受体工程，设计了一种新的TBT AIE PS，以显示聚集诱导的NIR发射集中在810 nm处，在300至700 nm范围内具有宽的吸收率，摩尔吸收系数大，O-1高（2）白光照射下的产生效率。此外，通过将两条支链柔性链连接到TBT上的供体工程产生了TBTC8，它避免了纳米颗粒（NP）中TBT的强分子间相互作用，从而产生了在O-1（2）生成，吸收和发射方面具有优化的整体性能的TBTC8 NP。随后在体外和体内研究中得到的PDT结果表明，TBTC8 NP在实际应用中是有希望的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号